Interestingly, the GPR55 agonist O-1602 was recently reported to reduce cognitive deficits, pro-inflammatory cytokines and synaptic dysfunction in a mouse model of Alzheimer’s disease [32]. Here, GPR55 is linked to early-onset autosomal dominant Alzheimer disease.